Company intelligence / Profile preview

ZyVersa Therapeutics, Inc.

Ownership: Public · ZVSA
Development stage: Other

Overview

VAR200 has completed preclinical studies and will enter a Phase IIa trial in diabetic kidney disease in H1–2025. IC100 has completed preclinical proof-of-concept studies and an IND submission for obesity/metabolic complications is planned for H2–2025, with first-in-human trials expected to start in H1–2026. Preclinical data support potential utility of both programs across multiple inflammatory and renal indications.[5][7]

Therapeutic areas: CardiovascularNeurologyMetabolic DisordersNephrology
Modalities: Monoclonal antibodies (mAbs)Small molecules (2-hydroxypropyl-beta-cyclodextrin)[1][9]
Industry: Biotech

Drug pipeline

1 asset

IC100

Preclinical

Partnerships

{"partner":"George Clinical","type":"CRO partnership for clinical trials"} [5]{"partner":"The Michael J. Fox Foundation","type":"Research funding collaboration on Parkinson's"} [7]

Financials

Market cap: $8.1K
Total revenue: $0
Enterprise value: $897.3M

Beyond the preview

Go deeper on ZyVersa Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZyVersa Therapeutics, Inc..